Potential clinical value of interleukin-31 and interleukin-33 with their receptors expression as diagnostic and predictive factors in endometrial cancer: a case-control study

Xi Zeng; Jing Li; Le-Ni Kang; Ming-Rong Xi; Guang-Dong Liao

Potential clinical value of interleukin-31 and interleukin-33 with their receptors expression as diagnostic and predictive factors in endometrial cancer: a case-control study

Int J Clin Exp Pathol. 2020 Jun 1;13(6):1324-1332. eCollection 2020.

Authors

Xi Zeng^{1

2}, Jing Li³, Le-Ni Kang^{2

4}, Ming-Rong Xi^{1

2}, Guang-Dong Liao^{1

2}

Affiliations

¹ Department of Gynecology and Obstetrics, The West China Second University Hospital, Sichuan University Chengdu 610041, China.
² Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education Chengdu 610041, China.
³ Department of Environmental and Occupational Health, West China School of Public Health, Sichuan University Chengdu, Sichuan, China.
⁴ National Office for Maternal and Child Health Surveillance of China, West China Second University Hospital, Sichuan University Chengdu, Sichuan, China.

PMID: 32661468
PMCID: PMC7344009

Abstract

Aims: To evaluate the potential role of interleukin-31 and interleukin-33 in diagnosis and prognosis from endometrial cancer. Methods: Tissue samples and clinical data were collected from 260 patients with endometrial cancer and 150 control patients with benign uterine diseases. Immunohistochemistry and ELISA testing quantified the expressions of interleukin-31 and interleukin-33 and their receptors. After surgery, all patients were followed up for an average of 56.3 months. Surgical effects were evaluated based on the patients' symptoms and signs. A two-sided P value <0.05 was considered significant. Results: IL-31, IL-33 and their receptors were significantly accumulated with the progression of endometrial cancer, in comparison to the controls. Moreover, the expressions were correlated with clinical characteristics, including tumor stage, differentiation, and associated with patients' disease-free survival. Conclusions: Limited data was available between the expressions of IL-31 and IL-33 and the receptors in patients with endometrial cancer. Our study findings suggested that the expressions of IL-31 and IL-33 might become possible biomarkers for the diagnosis and prediction in endometrial cancer.

Keywords: IL-31/IL-31R; IL-33/ST2; biomarkers; endometrial cancer.